2003 Fiscal Year Final Research Report Summary
Development of anti-parkinsonian drug using structure-activity relationship
| Project/Area Number |
14370757
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
医薬分子機能学
|
|---|
| Research Institution | HIROSHIMA UNIVERSITY |
|---|
Principal Investigator |
OHTA Shigeru Hiroshima University, Graduate School of Biomedical Sciences, Professor, 大学院・医歯薬学総合研究科, 教授 (60160503)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIHARA Kazumi Hiroshima University, Faculty of Medicine, academic administrator, 医学部, 教務員 (20271067)
KITAMURA Shigeyuki Hiroshima University, Graduate School of Biomedical Sciences, Associate Professor, 大学院・医歯薬学総合研究科, 助教授 (40136057)
TOSHIHARA Shinnichi Hiroshima University, Graduate School of Biomedical Sciences, Associate Professor, 大学院・医歯薬学総合研究科, 助教授 (00037607)
KOTAKE Yaichiro Hiroshima University, Graduate School of Biomedical Sciences, Research Associate, 大学院・医歯薬学総合研究科, 助手 (20335649)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Keywords | Parkinson's disease / tetrahydroisogunoline / anti-parkinsonian drug / structure-activity relationship / 1MeTIQ |
|---|
| Research Abstract |
The purpose of this project is to elucidate an anti-parkinsonian drug. Our group has found that 1 MeTIQ is a very good candidate for the anti-parkinsonian drug. We studied the structure activity relationship for 1MeTIQ derivatives using inhibition of dopaminergic cell toxicity. As the results, 1-benzyl DIQ, an oxidative metabolite of 1-benzyl TIQ, has strong cell toxicity. So the matabolism is very important factor. 7-OH-1MeTIQ has the most potent anti-parkinsonian drug. So it is very suitable candidate for Parkinson's disease.
|
